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Abstract. A specific radioimmunoassay for type beta 
transforming growth factor (TGF-/3) was developed 
and used to show that human platelets treated with 
thrombin release TGF-~ as a consequence of degranu- 
lation. The thrombin concentrations required to in- 
duce release of TGF-t3 parallel those concentrations 
that release the alpha-granule marker, beta-thrombo- 
globulin. Related studies showed that TGF-/3 acts on 
early passage, explant cultures of bovine aortic 
smooth muscle cells by inhibiting the effect of mito- 
gens on proliferation of subconfluent cell monolayers 
yet synergizing with mitogens to stimulate growth of 
the same cells when cultured in soft agar. The results 
show that primary cultures of bovine aortic smooth 
muscle cells and established normal rat kidney cells 
behave similarly with regard to TGF-~3 action. More- 
over, the data suggest that platelet-mediated prolifera- 
tion of aortic smooth muscle cells in vivo may not 
result solely from the stimulatory effect of platelet- 
derived growth factor (PDGF), but rather from an 
interaction of platelet factors which has the intrinsic 
ability to limit as well as stimulate mitosis. 
T 
HE rate of fibroblast and smooth muscle cell division 
is controlled, in large part, by the action of peptide 
growth  factors  present  in  platelets.  Physiologically, 
these peptides are released  as a consequence of platelet de- 
granulation at sites of injury; together with growth factors in 
plasma, they stimulate mitosis of connective tissue cells (36, 
37, 47). The best studied of these platelet peptides is platelet- 
derived growth factor (PDGF), ~  a component of alpha-gran- 
ules ( 16, 17) that is a chemoattractant  (13, 4 l, 42) and mitogen 
(36, 37, 47) for fibroblasts and vascular smooth muscle cells. 
It is important that PDGF has also  been implicated in the 
etiology of proliferative  diseases.  Expression  of PDGF-like 
proteins is a common feature of many transformed cells (7) 
and the hallmark of transformation by simian sarcoma virus 
(l I, 52). Similarly, exposure of vascular smooth muscle ceils 
to PDGF (35) or PDGF-like proteins (10, 40, 43) may be an 
important component in the proliferation of  these cells during 
atherogenesis. 
We and others have shown that PDGF is only one of  several 
growth factors in human platelets (4-6, 9,  14, 26); type beta 
transforming growth factor (TGF-/~) can be purified (5) from 
platelets  with yields  similar to that of PDGF.  TGF-/~ is  a 
widely distributed growth factor in animal tissues (27), but 
platelets contain ~100-fold more TGF-fl than do the other 
cells or tissues examined to date (5). Consistent with the role 
of platelet factors as participants in wound repair, TGF-~ can 
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EGF.  epidermal growth  factor;  NRK,  normal rat  kidney;  PDGF,  platelet- 
derived growth factor; ~-TGF, type 3 transforming growth factor. 
stimulate cell proliferation, protein  synthesis,  and collagen 
production  in  an  in  vivo  wound  healing  system  (46).  A 
functional, epidermal growth factor (EGF)-like peptide is also 
present in human platelets (4, 6, 26), but lack of the purifed 
protein has precluded detailed studies of its structure and 
action. 
The initial in vitro studies with TGF-~ focused on its role 
in  cellular transformation (28, 30); this peptide stimulates 
growth of non-neoplastic fibroblastic  cells suspended in me- 
dium with  10%  serum and agar (conditions of anchorage- 
independent growth).  In  particular,  NRK fibroblasts  grow 
efficiently in soft agar when both TGF-/3 and EGF (or TGF- 
alpha, an EGF-like peptide) are added to the culture medium 
(1, 28, 30). AKR-2B fibroblasts require only the addition of 
TGF-/3 (50). Recent studies with TGF-/3 have demonstrated 
that this growth factor is actually a bifunctional regulator of 
cell  proliferation; in  addition to  its stimulatory effects  on 
anchorage-independent growth of mesenchymal cells, TGF-¢~ 
can inhibit the soft agar growth of many epithelial tumor cells 
and several fibroblastic cell lines (29, 49). In NRK cells, TGF- 
inhibits monolayer growth  of subconfluent cultures yet 
stimulates the growth of confluent monolayers and cells sus- 
pended in agar (29). 
The inhibitory effects of TGF-~ on monolayer cultures of 
NRK cells have not been observed in all studies (21), suggest- 
ing that culture conditions can alter the cellular response  to 
TGF-#. The widespread use of subcloned cell lines has further 
complicated the interpretation of TGF-~ action. Moses et ai. 
(24)  have  recently studied  the  effects  of TGF-~  on  early 
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of this growth factor in uncloned cell cultures. The results 
show that the growth factor requirement for colony formation 
of these  primary  fibroblasts  resembles that  of established 
AKR-2B  cells;  TGF-/3  stimulates  colony formation in  the 
absence of a detectable synergism with EGF. 
The experiments reported here were designed to examine 
the potential role of TGF-# as a mediator of cell proliferation 
during wound repair and atherogenesis. We show that im- 
munoreactive TGF-B is released from platelets during throm- 
bin-induced degranulation and that the same concentrations 
of thrombin release TGF-/3 and the alpha-granule marker (16, 
17) beta-thromboglobulin. We also show that TGF-B acts on 
explant cultures  of bovine aortic smooth  muscle  cells  by 
inhibiting growth when the cells are cultured as subconfluent 
monolayers and synergizing with EGF and PDGF to stimulate 
growth when the cells are cultured in soft agar.  The results 
suggest that release of TGF-/3 during platelet degranulation 
may be an important element in the regulation of smooth 
muscle cell division. 
Materials and Methods 
Growth Factors 
TGF-~ was purified from freshly drawn human platelets as described (5) except 
that urea was removed from the purified protein by deSalting with high pressure 
liquid chromatography (2). EGF was purified from mouse submaxillary glands 
similarly to described procedures  (39). Final  preparations  migrated as single 
bands during SDS PAGE, eluted as single peaks during analytical C-18 high 
pressure liquid chromatography,  and had amino acid compositions  in agree- 
ment with published values. Porcine PDGF (Bethesda Research Laboratories), 
was -95% pure as determined  by SDS gels and lacked TGF-B as determined 
by specific receptor binding assays. Human PDGF,  purified to homogeneity, 
was generously provided by Gary Grotendorst and Russell Ross. TGF-CJ, EGF, 
and albumin-free samples of PDGF were quantitated  by amino acid analysis. 
Growth factor-enriched  extracts of human platelets were prepared as described 
(5), freeze-dried, redissolved in 4 mM HCI, and  neutralized with protein-free 
culture  medium.  Protein concentration  of the extract was determined  by the 
Coomassie binding  procedure  (Bio-Rad Laboratories,  Richmond,  CA) using 
bovine plasma albumin as reference. All growth factor solutions were diluted 
into culture medium (see below) containing  1 mg/ml bovine serum albumin 
before use. Neutralized  solutions  of PDGF and platelet extract  were heated 
(100*C, 5-10  min) before use. 
Radioimmunoassay for TGF-t~ 
Rabbit antiserum  (N-113), prepared against keyhole limpet hemocyanin-cou- 
pied TGF-B from human platelcts, was titered by its ability to bind t251-1abeled 
TGF-/S (prepared as described in reference 12) and used for radioimmunoassay 
in an amount (0.5 ul/tube) that precipitated  50% of the bindable tracer. The 
titration  was performed  in siliconized Eppendoff tubes (l.5-ml capacity) by 
incubating (2 h at room temperature) selected volumes of antiserum or normal 
rabbit serum (both diluted to 125 #1 with buffer) with ~2~I-labeled TGF-~ (104 
cpm in 25 ul) and precipitating tbe bound label (1 h at room temperature with 
gentle rocking) with fixed Staphylococcus aureus cells, (Boehringer-Mannheim 
Diagnostics, Houston, TX; 25 uI diluted with  1 ml buffer). Precipitated radio- 
activity was collected by high-speed centrifugation (I min, table-top centrifuge, 
Brinkmann  Instruments Co.,  Westbury,  NY), the  supernatant  was carefully 
aspirated,  and  the  tube  with  the  pellet  was counted  for  radioactivity.  The 
radioimmunoassay was performed under similar conditions except that selected 
amounts of unlabeled  TGF-t3 from  human platelets (diluted  to 0.1  ml with 
buffer) were incubated (2 h at room temperature)  with antiserum (0.5 ul in 25 
ul buffer) before the addition  of labeled TGF-t3. The buffer for both titration 
and radioimmunoassay was a solution of 0.1 M Tris, 0.5% Nonidet P-40, 0,1% 
SDS, 0.15 M  NaC1 that  had  been  brought to pH  8.0  with  HCI and  then 
supplemented  with crystalline bovine serum albumin and aprotinin  solution 
(2% of each as final concentrations;  Sigma Chemical Co., St. Louis, MO). The 
S.  aureus cells were washed three times (by repeated  suspension and centrif- 
ugation) with a  10-fold excess of buffer per wash, and suspended to half the 
original volume before use. Data are plotted as means of duplicate determina- 
tions. Each data point usually varied from its mean by <5%. 
Platelet Release Reaction 
Human platelet-rich  plasma (4 ml, Community Blood and Plasma, Baltimore, 
MD) was purified by gel filtration over a siliconized column (1.5 x  30 cm) of 
Sepharose 2B equilibrated in calcium-free Tyrode's solution (18) and run at a 
flow rate  of  15-25 ml/h.  The gel-filtered platelets  were  collected  in  l-ml 
fractions,  quantitated  with  a  Coulter  counter,  and  suspended  (10S/ml) in 
calcium-free Tyrode's solution. Aliquots (0.9 ml) of the suspension were incu- 
bated with gentle mixing (in siliconized test tubes) in a 37"C water bath for 5 
rain before the addition of 0,1  ml of a thrombin solution (diluted in Calcium- 
free Tyrode's soultion,  37"C, 0-1  U/ml final concentration;  Sigma Chemical 
Co.). After 3 rain with thrombin, the supernatant  (containing released platelet 
factors) was collected by centrifugation. Careful collection of the top 80-90% 
of the supernatant  prevented contamination  of the Sample with platelets. 
Cell Cultures 
NRK fibroblasts (clone 49F) were maintained  in Dulbecco's modified Eagle's 
medium containing gentamicin (DME) and 5% fetal bovine serum (Bio-Fluids 
Inc., Rockville, MD). Bovine vascular smooth muscle cells were obtained  by 
explant culture  from the medial layer of fetal bovine aorta  as described (13, 
34). In brief, the explants were cultured in T-75 flasks with DME,  10% in fetal 
calf serum. The cultures were fed biweekly and trypsinized after 3-4 wk. The 
trypsinized cultures were suspended in medium and filtered through four layers 
of sterile gauze  to remove  the  small  pieces of medial  aorta.  The resulting 
preparations of smooth muscle cells (defined as passage 1  ) were placed in two 
T-75 tissue culture flasks, maintained in medium with 5% fetal bovine serum, 
and thereafter split in a 2:1 ratio. Smooth muscle cells used in the experiments 
reported here were at passages 2-4. 
Assays for Cell Growth 
Cell growth was measured in both soft agar and monolayer culture. The soft 
agar assay was performed as described (5, 31) with 3,000 cells seeded in DME 
containing  10% calf (whole blood-derived) serum (Gibco, Grand Island, NY) 
or  10%  bovine  plasma-derived  serum.  (Bovine plasma  was prepared  at  the 
National Institutes of Health-Poolesville Animal Center by plasmaphoresis of 
4-12-rap-old  calves. The plasma was sterilized by filtration and convened to 
10% plasma-derived serum in DME as described in reference 4.) To measure 
mitosis of NRK and smooth muscle cells in monolayer culture,  1.4-ml portions 
of a cell suspension (3,000 cells/ml) were added to tissue culture dishes (35 x 
100 ram;  resulting monolayers were ~10%  confluent) and incubated for 8 d. 
At selected intervals the cultures were trypsinized, and the number of cells was 
determined  with a Coulter counter.  The medium for monolayer cultures was 
DME  with  5%  plasma-derived serum;  5%  fetal calf serum;  or 5%  plasma- 
derived serum containing 0.1 nM EGF. In some experiments, TGF-/~ (20 pM) 
was added to the cultures 4-6 h after seeding. Stimulation  of DNA synthesis 
by PDGF was determined  with both smooth muscle and NRK cells cultured 
in  1%  plasma-derived  serum as described  (3) except  that  ~251-deoxyuridine 
(Amersham Corp.. Arlington Heights, IL 1 uCi/well) was used instead of [3H]- 
thymidine. In some experiments, the assay was modified to examine stimulation 
of DNA synthesis by EGF and TGF-/3 (see the legend to Table 1 for details). 
Results 
Initial experiments were designed to study the release of TGF- 
/~ during platelet degranulation. A radioimmunoassay, rather 
than a bioassay, was used to examine the released products 
for TGF-~, thus minimizing the likelihood that other released 
platelet factors, such as PDGF (16,  17), might interfere with 
TGF-~ quantitation.  Fig.  l  shows  the characteristics of the 
radioimmunoassay developed for TGF-/L Antiserum (N- l 13), 
generated  in  rabbits  against  keyhole limpet  hemocyanin- 
coupled TGF-~ from human platelets,  effectively bound the 
radioiodinated growth factor: 50% of maximal immunopre- 
cipitation occurred with 0.5  #l of the unfractionated, heat- 
inactivated serum (Fig. l, inset, solid circles). This amount of 
antiserum was used under conditions of radioimmunoassay 
(Fig.  l) and detected ~0.5 ng unlabeled TGF-/~. PDGF (0. l- 
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Figure 1.  Radioimmunoassay for TGF-/L The figure shows specific 
binding of radiolabeled TGF-/3 to antiserum  N-113 and  use of the 
antiserum under conditions of radioimmunoassay, e, antiserum. ©, 
normal rabbit serum. See Materials and Methods for protocols. 
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Figure 2.  Release of TGF-~ and beta-thromboglobulin by treatment 
of human platelets with thrombin. Gel-filtered human platelets were 
degranulated by exposure to thrombin (see Materials and Methods). 
The supernatants  were tested for presence of beta-thromboglobulin 
(©) and TGF-~ (e) using a commercial radioimmunoassay kit (Amer- 
sham Corp.) and the assay  described in Fig.  1,  respectively. TGF-/~ 
detection required concentration of the supernatant (0.5-ml portions 
of the  supernatants  were  dialyzed  against  1  M  acetic  acid  in  a 
microdialysis  unit  [Bethesda  Research  Laboratories],  freeze-dried, 
and dissolved in 0.1  ml of radioimmunoassay buffer (see legend to 
Fig.  l) modified such that the final albumin concentration was 20 
mg/ml).  When  this  entire  sample  was  assayed  (corresponding  to 
released products from 0.5 x  108 platelets), immunoreactive TGF-/3 
was detected at 0.8-5 ng (for 0.01-0.3  U of thrombin, respectively). 
Immunoreactive beta-thromboglobulin was detected at 20 to 100 ng 
after a  10- to 20-fold dilution of the supernatants  into radioimmu- 
noassay buffer. The basis for the apparent decrease in release of TGF- 
¢~ with 1 U/ml thrombin is not clear at present. 
100 ng), EGF (0.1-1,000 ng), and insulin (0.1 - 1,000 ng) were 
not  detected  at all by the  immunoassay (data  not  shown). 
Others have shown that this antiserum also neutralizes the 
activity of TGF-t3 in bioassays (23). 
Fig. 2 shows the use of the immunoassay to examine release 
of TGF-/3 from fresh gel-filtered human platelets after their 
degranulation with thrombin. The results show that thrombin 
treatment efficiently releases immunoreactive TGF-/3 (solid 
circles). Moreover, the concentrations ofthrombin that release 
the growth factor agree well with those concentrations that 
release the alpha-granule marker (16,  17) beta-thromboglob- 
ulin (open circles).  Quantitative analysis of the data in Fig. 2 
indicates that a  single human  platelet releases  1,200-2,400 
molecules of TGF-/3. A similar value (2,500 molecules TGF- 
13 per platelet) can be derived from the yield of the growth 
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Figure 3.  Effect of TGF-t3  on growth of smooth muscle and NRK 
cells in monolayer. Sparse monolayers of smooth muscle cells (A) 
and  NRK cells (B) were prepared as described in  Materials and 
Methods and cultured in DME containing 5% plasma-derived serum 
(squares) or 5% plasma-derived serum, 0.1 nM in EGF (circles). The 
experiment was performed in the presence (open symbols) and ab- 
sence (filled symbols) of TGF-/3 (20 pM). 
factor after purification (assuming 20%  recovery of TGF-/3 
[2,  5]),  demonstrating that platelet degranulation releases a 
large part of intracellular TGF-B. These results support other 
studies showing that TGF-/~ stimulates protein synthesis and 
cell division in a rat wound healing system (46). 
In addition to the physiological release of PDGFs during 
wound repair, these peptides may have an important role in 
atherogenesis; other investigators have suggested that expo- 
sure to PDGF, or PDGF-like molecules, may be an important 
component in the proliferation of aortic smooth muscle cells 
(35, 43). We have examined the effect ofTGF-¢/on monolayer 
and soft agar growth of explant cultures from bovine aortic 
smooth muscle. 
As expected from the work of others (36,  37), sparse mon- 
olayers of these cells (Fig. 3A) became quiescent when main- 
tained in medium containing 5 % plasma-derived serum (solid 
squares) and divided regularly when the medium contained 
5%  whole  blood-derived  serum  (data  not  shown)  or  5% 
plasma-derived serum,  0.1  nM  in  EGF (solid circles).  The 
addition of TGF-¢/did not stimulate growth of the quiescent 
cells (open squares) and antagonized the effect of EGF in the 
growing  cultures  (open  circles).  Control  studies  (data  not 
shown) demonstrated that TGF-/3 also inhibited the effect of 
5% calf serum on smooth muscle cell growth in monolayer. 
Interestingly, these effects of TGF-/3 on vascular smooth mus- 
cle cells are strikingly similar to those observed for the mon- 
olayer growth of established NRK flbroblasts studied in par- 
allel  and under identical  conditions (Fig.  3B and reference 
29). 
The  similar  effects of TGF-¢/  on  monolayer  growth  of 
vascular smooth muscle and NRK cells was confirmed in a 
mitogen assay measuring [3H]thymidine incorporation after 
incubation of growth factors for 22 h with confluent serum- 
starved cells (Table I). TGF-fl did not stimulate incorporation 
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ThymidineIncorporation in Monolayer Cell Cultures
The table shows the ability of EGF, calfserum, and TGF-O to stimulate ['H]-
thymidine incorporation into DNA of serum-starved confluent cells . The
experiment was performed similarly to the procedure described (5) . In brief,
cells were seeded in 96-well plates in DME, 5% calf serum . The next day, the
medium was changed to DME, 0.2% calf serum . Cells were incubated in this
low-serum medium for 3 d, during which theybecameconfluent and quiescent .
Growth factors were incubated with the quiescent cells for 15 to 35 h before
the addition of ['H]thymidine . After a 7-h pulse with the radiolabel (22 or 42
h total incubation with growth factor), the cells were fixed with 5% trichloroa-
cetic acid, washed, extracted, and counted for radioactivity. EGFand TGF-ß
were tested at concentrations active in both monolayer (see Fig. 3) and soft
agar (see Fig. 4) cultures. EGF was tested under standard mitogen assay
conditions for mesenchymal cells (about 22-h prereplicative phase), whereas as
TGF-,3 was tested under both standard and prolonged (42 h prereplicative
phase) assay conditions . Calf serum (5%) was considered the positive control
under both conditions. ND, not determined .
of ['H]thymidine in this system despitethe fact thatEGFand
calf serum were effective mitogens . Shipley et al . (44) have
reported that in quiescent AKR-2B cells, TGF-O stimulates
mitosis after aprolongedprereplicative phase of 30-42 h. We
have examined the effects ofTGF-0 on ['H]thymidine incor-
poration under similar conditions (Table 1, 42 h), but, again,
could not detect an overall stimulation of DNA synthesis in
smooth muscle or NRK cells. These results distinguish the
effects ofTGF-ßin smooth muscle andNRKcellsfrom those
in AKR-2B cells . Massagué (21) has reported that TGF-O
stimulates mitosis of sparse, serum-starved NRK cells . We
perform mitogen assays with confluent cultures, but our
results with ['H]thymidine incorporation agree with the effect
ofTGF-Oon thelong-term monolayergrowth of subconfluent
cells cultured in plasma-derived serum (see Fig . 3) .
When bovine aortic smooth muscle cells are suspended in
medium containing 10% serum and agar, their rate of growth
(colony formation) is stimulated, rather than inhibited, by the
addition of TGF-ß (Fig. 4A, solid circles) . In this culture
system, the effect ofTGF-ß is only observed when both EGF
and PDGF are also added; absence of exogenous EGF (Fig .
4A, open circles and Fig . 4B) or PDGF (Fig. 4A, open
triangles) decreases colony formation 5- or 10-fold, respec-
tively . Again, thesegrowth factor effectson colony formation
of smooth muscle cells resemble those for NRK fibroblasts,
especially with regard to the EGF dependency of colony
formation (compare Fig . 4B with references 1, 4, 28, 30) .
Comparativedose response curves for the growth factors used
by NRK and smooth muscle cells in soft agar showed that
colony formation in the two cell types is induced by similar
concentrations ofTGF-ß andEGF. However, the amount of
PDGF required to induce colony formation of smooth muscle
cellsexceeds that required byNRKfibroblasts . InNRKcells,
the need for PDGF is satisfied by culturing the cells in soft
agar containing 10% serum ; PDGF must be added to this
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Figure 4 . Effect of TGF-O on growth of smooth muscle cells in soft
agar. The assaywasperformed as described in Materialsand Methods
in medium containing 10% calfserum . For the experiment shown in
A, the assay was supplemented with 1 nM PDGF and 0.5 nM EGF
(0), 1 nM PDGF (O), or 0.5 nMEGF(A) . For the experiment shown
in B, the assay was supplemented with 1 nM PDGF and 20pM TGF-
13 .
Figure 5 . Ability of purified PDGF to stimulate monolayerand soft
agar growth of smooth muscle cells . A shows the concentrations of
purified PDGF required to stimulate growth of smooth muscle cells
cultured in monolayer (O) and soft agar (E, 0), The assays were
performed as described in Materials and Methods except that the
medium for both culture conditions was DME with 10% plasma-
derived serum . The soft agar cultures were supplemented with TGF-
0(20 pM) and EGF (0 .5 nM) in order to elicit thePDGF effect . Both
assays were incubated at 37 °C for 7 d . Bshows the ability ofpurified
PDGF to stimulate "'I-deoxyuridine incorporation into trichloroa-
cetic acid-insoluble products in smooth muscle (O) and NRK (0)
cells. Basal 12'1-deoxyuridine incorporation was 1,700and7,250cpm
for smooth muscle and NRK cells, respectively . Maximal stimulation
for PDGF was defined as the response of cells to 100 ng/ml of the
purified growth factor.
system only when the cells are grown in 10% plasma (4) . In
contrast, colony formation of early passage bovine smooth
muscle cells cultured in 10% calfserum(Fig . 4A) still requires
['H]Thymidine incorporation (cpm x 10-'/well)
Smooth muscle NRK
Growth factor 22 h 42 h 22 h 42 h
None 4 4 50 40
EGF (0 .1 nM) 12 ND 190 ND
Calf serum (5%) 100 70 250 166
TGF-/3
1 PM 5 3 47 45
10 PM 4 2 33 29
100 PM 4 3 14 42the addition of PDGF. 
The experiments shown  in  Fig.  5  examined the  PDGF 
requirement of the  smooth  muscle cells  in  detail.  For the 
results shown in Fig.  5A, cells were grown in soft agar con- 
taining 10% plasma-derived serum (rather than whole blood- 
derived serum) in order to decrease the background levels of 
platelet-derived peptides. Under these conditions, overall col- 
ony formation (colonies of >40 um diam,  -10 cells,  solid 
squares) is induced (in the presence of saturating amounts of 
TGF-13 and EGF) with concentrations of PDGF that are just 
slightly greater than those that stimulate cell growth in mon- 
olayer (Fig. 5, open c!rcles). Efficient cell division in soft agar 
(formation of colonies greater than 60 microns in diameter, 
solid circles)  requires about  10-fold more PDGF than does 
division in monolayer. Identical results were obtained with 
each of the three PDGF preparations described in Materials 
and Methods. Note that stimulation of smooth muscle cell 
division in monolayer (open circles) is induced by the same 
concentrations of PDGF that are active in other systems (4, 
15, 38, 53), and that smooth muscle and NRK cells respond 
equivalently to PDGF in a monolayer assay measuring stim- 
ulation of DNA synthesis (Fig. 5 B). Thus, the high concen- 
tration  of PDGF  required  to  induce  colony formation of 
smooth muscle cells does not reflect an overall insensitivity 
to this growth factor. 
Despite the fact that the PDGF preparations used in these 
studies were purified to homogeneity by distinct methodolo- 
gies (32, 48) and exhaustively heated (100*C, 5-10 min) before 
use,  we have considered the possibility that stimulation of 
smooth muscle cell growth in soft agar by high concentrations 
of PDGF might be due to heat-stable contaminants in the 
preparations rather than to PDGF itself. If small amounts of 
contaminating platelet factors were responsible for induction 
of colony formation in these preparations of purified PDGF, 
then crude PDGF should stimulate soft agar growth of  smooth 
muscle cells more efficiently. We have used a heated platelet 
extract as a source of highly impure PDGF and show (Fig. 6) 
that colony formation  of vascular smooth muscle cells (as- 
sayed in the presence of saturating concentrations of TGF-fl 
and EGF, solid symbols) still requires more PDGF than does 
stimulation of DNA  synthesis in monolayer (open circles). 
Moreover, the quantitative relationship between the amount 
of PDGF that stimulates DNA synthesis in monolayer, small 
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Figure 6.  Ability of a crude platelet extract to stimulate monolayer 
and soft agar growth of smooth muscle cells.  The figure shows the 
concentrations of a heated platelet extract (see Materials and Meth- 
ods) that stimulates eSl-deoxyuridine incorporation in monolayer (©) 
and colony formation in soft agar (ll, 0). See the legend to Fig. 5 for 
details of the soft agar and monolayer assays. 
colony formation, and large colony formation is identical for 
both pure and crude PDGF (compare Figs.  5 and 6;  open 
circles,  filled  squares,  and  closed circles,  respectively). We 
conclude that high concentrations of  PDGF itself  are required 
to  synergize with  TGF-fl and  EGF  and  stimulate  colony 
formation of bovine aortic smooth muscle cells. 
Discussion 
We have developed a specific radioimmunoassay for TGF-fl 
and shown that this growth factor is released from platelets 
degranulated with thrombin. Note that the concentrations of 
thrombin that release  TGF-/~ also release the alpha-granule 
marker  beta-thromboglobulin.  These  results  suggest  that 
TGF-fl, like PDGF (16,  17), is contained within the platelet 
alpha-granule,  but  a  direct  analysis  of TGF-fl content  in 
isolated alpha-granules remains an important matter for fur- 
ther study. Similarly, recent studies have shown that certain 
cell lines secrete TGF-fl in a biologically inactive state (8, 20); 
the  activity can be  expressed in  vitro by exposure of the 
growth factor to acid (pH 2). We are currently examining the 
biological state of TGF-fl in platelets. 
In  addition to the generally accepted role of PDGFs in 
wound repair, Ross and Glomset have suggested that exposure 
of aortic smooth muscle cells to PDGF may stimulate prolif- 
eration of smooth muscle cells in atherogenesis (35). In vivo 
model systems examining the effect of platelet adhesion and 
degranulation on proliferation of aortic smooth muscle cells 
have yielded conflicting results (34,  45),  but it is clear that 
aortic smooth muscle cells in culture do proliferate in response 
to PDGF. The data reported here show that platelet-derived 
TGF-fl also  acts on cultures of aortic smooth muscle cells. 
The effect of TGF-13 on these cells depends on conditions of 
cell morphology and culture; TGF-fl inhibits proliferation of 
subconfluent  monolayers  yet  stimulates  EGF-dependent 
growth of the cells when suspended in soft agar. These effects 
are qualitatively identical to those observed with NRK cells 
(reference 29 and this report) and thereby identify a primary 
cell  that  behaves  similarly to  established  NRK  cells  with 
regard to TGF-/~ action. Of particular interest is the important 
role of EGF in colony formation of smooth muscle cells (Fig. 
4) despite its rather weak effect on stimulating mitosis of these 
cells in monolayer (Table I). An appropriate interpretation of 
these results will require further study. 
Two differences between the effects of TGF-fl on growth of 
smooth muscle and NRK cells are that colony formation of 
NRK cells is more efficient and requires less PDGF than does 
that of smooth muscle cells. Both of these differences may 
well be due to the nature of the NRK cells (line 49F) used in 
these studies;  the cells were specifically  selected for efficient 
growth in soft agar (Joseph De Larco, personal communica- 
tion).  For an  unselected, early passage  cell,  the growth of 
explant cultures of bovine smooth muscle ceils in soft agar is 
reasonably efficient: at least half of the seeded cells will divide 
in soft agar in response to optimum concentrations of growth 
factors, and -15% of the cells will divide many times to form 
relatively large colonies (of>60 um diam). The high amounts 
of PDGF needed to stimulate anchorage-independent growth 
of smooth muscle cells, in fact, complements other studies (1, 
19, 22, 50) showing that cells of mesenchymal origin can have 
quantitatively different growth factor requirements for colony 
formation. When suspended in soft agar containing 10% calf 
Assoian and Sporn TGF-~ Mediates Platelet Action  1221 serum, colony formation of mesenchymal cells may require 
the addition of EGF (Rat-1  ceils);  TGF-B  (AKR-2B  cells); 
EGF and TGF-~ (NRK cells); EGF, TGF-B, and insulin-like 
growth factor (BALB/c 3T3 cells); or EGF, TGF-/3, and PDGF 
(smooth muscle cells; this report). 
Studies  by  Seifert  et  at.  (40)  have  shown  that  explant 
cultures of smooth muscle cells from pup, but not adult, rat 
aorta produce mitogenic concentrations of a PDGF-Iike pep- 
tide. Nilsson et al.  (25) have reported that adult rat smooth 
muscle cells, isolated by collagenase digestion of aortic media, 
secrete  a  PDGF-Iike  peptide upon their "modulation" to a 
mitotic phenotype. In contrast to these reports,  the explant 
cultures  of  fetal  bovine  aortic  smooth  muscle  cells  used 
throughout this study did not appear to secrete large amounts 
of  a  PDGF-like  peptide  as  determined  by  stimulation  of 
mitosis  with  exogenous  PDGF  (Fig.  5)  and  induction  of 
quiescence  in  subconfluent  cultures  with  plasma-derived 
serum (Fig. 3A). 
The results presented here raise the possibility that growth 
of vascular smooth muscle cells  in response to platelet de- 
granulation may not be due to PDGF alone but rather to an 
interaction of platelet-derived peptides that has the intrinsic 
ability  to  limit  as  well  as  stimulate  mitosis.  Interestingly, 
several lines of evidence suggest that the high concentrations 
of PDGF required to elicit the stimulatory effect of TGF-/3 in 
smooth  muscle cell  culture may be  present during athero- 
genesis. First, as suggested by the response-to-injury hypoth- 
esis (35), platelet release may act as a point source for growth 
factors; the concentrations of TGF-~, PDGF, and the EGF- 
like peptide (4) may be high for aortic smooth muscle cells 
near  sites  of platelet  release.  Second,  endothelial  cells  in 
culture produce  PDGF-Iike  peptides  (i0)  and  may  supply 
medial smooth muscle cells with PDGF in vivo. Third, acti- 
vated macrophages release PDGF in vitro, and these cells are 
an  important component of the  atherosclerotic aorta (43). 
Fourth,  it  is  possible  to prepare  cultures of aortic  smooth 
muscle  cells  that themselves  produce a  PDGF-Iike  peptide 
(25, 51). Taken together with previous studies (11, 35, 36, 46, 
52), the results presented here extend the interface of PDGF 
and TGF-~ biology and suggest  that both platelet peptides 
have  potential  roles  in  wound  repair,  transformation,  and 
atherogenesis. 
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